Thursday, January 19, 2017 9:01:25 PM
Lol...I'm going for it. I read through to page 28. I quit.
Assuming that all 19,945,132 Units are sold in the Rights Offering (which number is an estimated maximum amount of Units, calculated by using the number of shares of common stock and Listed Warrants outstanding as of December 30, 2016 and including in such amount the number of shares of common stock issuable upon conversion of the remaining outstanding shares of Series B Preferred Stock as of December 30, 2016), after deducting fees and expenses payable to the dealer-manager, and after deducting other expenses payable by us, we estimate the net proceeds of the Rights Offering will be approximately $ million. We intend to use approximately $15.6 million of the net proceeds from the exercise of Subscription Rights for clinical development, consisting of: approximately $9.3 million to expand the geographic scope necessary to complete patient accrual in our ongoing phase 3 clinical trial of PV-10 to treat locally advanced cutaneous melanoma; approximately $3.6 million to complete patient accrual in the phase 1b portion and begin the phase 2 portion of our phase 1b/2 combination study of PV-10 and Merck’s
KEYTRUDA in late stage melanoma; approximately $1.2 million to conduct our phase 1b/2 study of PV-10 in liver cancer (hepatocellular carcinoma); and approximately $1.5 million to conduct exploratory pre-clinical studies and phase 1 clinical studies to support current and future oncology indications. We intend to use any remaining net proceeds for working capital and general corporate purposes. See “Use of Proceeds.”
p.22
Page 28 & 29 Contain info about Culpepper and Dees
https://www.sec.gov/Archives/edgar/data/315545/000119312517013156/d274304ds1a.htm
GLTA
Recent PVCT News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 05:57:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/06/2024 05:56:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 02:22:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 08:16:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 07:12:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 02:30:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 04:12:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:54:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 08:16:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/01/2024 10:29:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 09:21:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 07:55:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:56:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 04:39:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:07:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 05:49:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/30/2023 11:51:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 10:23:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 04:35:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 01:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/27/2023 09:55:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 09:16:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/05/2023 04:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 11:07:30 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM